GHRP-6

What GHRP-6 Does

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates growth hormone release from the anterior pituitary. It was one of the first synthetic GH secretagogues developed, created by Cyril Bowers and colleagues in the 1980s during foundational research into the ghrelin/GHS-R1a receptor system. GHRP-6 is the most potent appetite stimulator of all GHRPs — its aggressive activation of the ghrelin receptor produces intense hunger signaling alongside meaningful GH release.

The mechanisms that matter:

• GHS-R1a (ghrelin receptor) agonism — binds the same receptor as endogenous ghrelin on pituitary somatotrophs, triggering GH release. GHRP-6 is one of the more potent ghrelin mimetics, producing a strong, rapid GH pulse within 15–30 minutes of injection
• Ghrelin-mediated appetite signaling — GHRP-6’s activation of hypothalamic GHS-R1a receptors triggers the same intense hunger cascade as endogenous ghrelin. This includes increased gastric motility, neuropeptide Y (NPY) release, and orexigenic signaling. This is not a mild effect — it is the strongest appetite stimulation of any injectable GH peptide
• Secondary cortisol and prolactin elevation — unlike the highly selective Ipamorelin, GHRP-6 activates pathways that mildly increase cortisol (via ACTH stimulation) and prolactin. At standard 100 mcg doses, these elevations are modest. At 200–300 mcg, they become more significant
• Synergy with GHRH analogs — like all GHRPs, GHRP-6 works synergistically with GHRH-pathway peptides (CJC-1295, Sermorelin). The GHRP provides the “release” signal; the GHRH provides the “amplify” signal. Combined, GH output exceeds the sum of individual effects
• Gastric protective effects — GHRP-6 has been shown to stimulate the release of gastric protective factors and promote mucosal healing, a secondary benefit unrelated to GH release. Research from the Center for Genetic Engineering and Biotechnology (CIGB) in Havana has explored GHRP-6 for gastric cytoprotection

GHRP-6 vs Other GHRPs

This is the essential comparison. Each GHRP activates the same receptor but with different selectivity profiles:

Feature	GHRP-6	GHRP-2	Ipamorelin	Hexarelin
GH release potency	Strong	Strongest	Moderate	Very strong (single dose)
Appetite stimulation	Severe	Moderate	Minimal	Mild
Cortisol elevation	Mild–moderate	Mild	None (standard dose)	Significant
Prolactin elevation	Mild	Mild	None (standard dose)	Significant
Desensitization risk	Low	Low	Low	High (2–4 weeks)
Best for	Bulking, hard-gainers	Maximum GH output	Clean GH, anti-aging	Short-term max GH pulse
Side effect burden	Moderate	Low–moderate	Low	High

When to choose GHRP-6: You want strong GH release AND you either need or don’t mind the intense appetite stimulation. This makes GHRP-6 uniquely suitable for underweight individuals, bodybuilders in a bulking phase, or anyone recovering from caloric deficit who needs help eating enough. If you’re trying to lose fat or maintain body composition, the appetite spike actively works against your goals — choose Ipamorelin instead.

When to avoid GHRP-6: You’re cutting weight, managing caloric intake, or prioritize a clean side effect profile. The cortisol elevation, while mild at 100 mcg, adds an unnecessary variable. Ipamorelin delivers 80% of the GH release with none of these concerns.

Dosing Protocol

Standard Protocol (With CJC-1295)

Parameter	Detail
Dose	100 mcg GHRP-6 + 100 mcg CJC-1295 (no DAC) per injection
Frequency	2–3 times daily
Best timing	Morning (fasted), post-workout, pre-sleep
Cycle length	8–12 weeks on, 4 weeks off
Route	Subcutaneous injection

The pre-sleep dose matters most for GH optimization. It amplifies the natural nocturnal GH surge. However, the pre-sleep dose is also when the appetite spike is most manageable — you’re about to sleep through it.

Dose Tiers

Level	GHRP-6 Dose	GH Release	Appetite Spike	Cortisol Risk
Conservative	100 mcg, 2x daily	Good	Manageable	Negligible
Standard	100 mcg, 3x daily	Strong	Significant per dose	Minimal
Aggressive	200 mcg, 2–3x daily	Very strong	Intense	Moderate
Maximum	300 mcg, 3x daily	Near saturation	Severe	Meaningful

Stay at 100 mcg per dose. GH release from GHRPs follows a saturation curve — doubling the dose does not double GH output. However, appetite stimulation and cortisol elevation scale more linearly with dose. The 100 mcg dose provides the best ratio of GH benefit to side effect burden. Going above 200 mcg per dose rarely justifies the trade-offs.

Fasting Requirements

Non-negotiable for all GH peptides:

• Fast 2+ hours before injection — insulin is the primary suppressor of GH release at the pituitary level. Even a moderate insulin spike from a mixed meal will blunt the GH pulse by 50% or more
• Wait 30–60 minutes after injection before eating — allow the GH pulse to peak and begin clearing. With GHRP-6, this is the hardest part — the hunger spike hits at 20–30 minutes post-injection, exactly when you need to keep fasting
• Strategies for the hunger spike: Inject immediately before bed. If dosing during the day, have your meal pre-prepared so you can eat as soon as the 30-minute window passes. Drinking a large glass of water or sparkling water helps some users bridge the gap
• Pre-sleep window is naturally fasted — this is the easiest dose for compliance

GHRP-6 Alone (Without CJC-1295)

Parameter	Detail
Dose	100–200 mcg per injection
Frequency	2–3 times daily
Cycle length	8–12 weeks on, 4 weeks off

Running GHRP-6 alone produces a respectable GH pulse but the synergy with a GHRH analog (CJC-1295 or Sermorelin) amplifies the response 3–5x. The combination is strongly recommended.

Reconstitution

For a 5 mg vial of GHRP-6 — add 2.5 mL bacteriostatic water:

Dose	Volume to Draw
100 mcg	5 units on insulin syringe
200 mcg	10 units
300 mcg	15 units

Concentration: 2,000 mcg/mL. One 5 mg vial provides 50 doses at 100 mcg — roughly 17–25 days at 2–3 doses per day.

Combining with CJC-1295: Draw GHRP-6 from its vial, then insert the same needle into the CJC-1295 vial and draw the second peptide. Inject together immediately. Never pre-mix vials for long-term storage.

Storage: Refrigerate at 2–8°C. Use within 28 days of reconstitution. Unreconstituted powder can be stored frozen.

Cycling

• Standard: 8–12 weeks on, 4 weeks off
• Rationale: Cycling allows for assessment of results and prevents potential long-term cortisol/prolactin elevation from becoming clinically significant. GHRP-6 does not desensitize as quickly as Hexarelin, but cycling is still considered best practice
• During off-cycle: MK-677 (oral) can be used as a bridge to maintain some GH elevation without the injection burden. See the MK-677 Protocol

What to Expect

Realistic Timeline

• Week 1: Immediate hunger spikes after each injection. Sleep quality often improves within the first few nights (especially with pre-sleep dosing). May notice vivid dreams. No visible body composition changes
• Weeks 2–3: Appetite patterns become predictable and manageable. Recovery from workouts noticeably improves. Some users report better skin quality and minor water retention (indicates GH elevation)
• Weeks 4–6: Body composition shifts begin. Users in a caloric surplus notice improved muscle fullness and recovery. Weight gain (lean mass + water) is common in bulking protocols. Fat loss is possible if diet is controlled despite the appetite increase
• Weeks 6–8: Full effects are established. Improved sleep depth, accelerated recovery, better skin and hair quality. Strength and lean mass gains are apparent for those training consistently
• Weeks 8–12: Maximum benefits from the cycle. Transition to maintenance or off-cycle phase. Water retention reduces within 1–2 weeks of discontinuation

Who Benefits Most From GHRP-6

• Hard-gainers — the appetite stimulation is the feature, not a bug. GHRP-6 combined with a caloric surplus is one of the most effective natural appetite-boosting strategies
• Post-surgery or illness recovery — when appetite is suppressed and GH is needed for tissue repair
• Bulking bodybuilders — GH plus forced eating in a controlled surplus
• Individuals with naturally low appetite — especially if combined with MK-677 for compounding appetite effects

What the Research Says

GHRP-6 has one of the deepest research bases of any GH secretagogue, spanning decades of investigation:

Foundational GHS-R1a research: GHRP-6 was instrumental in the discovery of the ghrelin receptor (GHS-R1a). Cyril Bowers and colleagues at Tulane University synthesized GHRP-6 in the 1980s and used it to demonstrate that a novel receptor distinct from the GHRH receptor could trigger GH release. This work directly led to Kojima et al.’s 1999 identification of ghrelin as the endogenous ligand for GHS-R1a — a landmark in endocrinology. Published in Science.

Human GH release data: Multiple studies have documented dose-dependent GH release from GHRP-6 in healthy subjects. Bowers et al. showed that 1 mcg/kg IV produced GH peaks of 30–60 ng/mL within 15–30 minutes. The combination of GHRP-6 with GHRH produced synergistic GH release exceeding the sum of individual effects — a finding replicated across multiple research groups. Published in Journal of Clinical Endocrinology & Metabolism.

Appetite and ghrelin pathway: Studies confirmed that GHRP-6 activates the same orexigenic pathways as endogenous ghrelin — increasing neuropeptide Y (NPY) and agouti-related peptide (AgRP) signaling in the arcuate nucleus, stimulating gastric acid secretion and gastric motility. The appetite effect is pharmacologically indistinguishable from a ghrelin injection. Published in Endocrinology.

Cortisol and prolactin: Comparative studies between GHRPs demonstrated that GHRP-6 produces mild but measurable increases in cortisol (via ACTH stimulation) and prolactin at doses above 100 mcg. These elevations are transient and return to baseline within 2–3 hours. At the standard 100 mcg dose, cortisol increases are typically within physiological range. Published in Clinical Endocrinology.

Gastric cytoprotection: Research from the CIGB (Center for Genetic Engineering and Biotechnology) in Cuba demonstrated that GHRP-6 has gastric cytoprotective properties independent of GH release, promoting mucosal integrity and protecting against ischemia-reperfusion injury. This has been explored for potential applications in surgical healing and gastroprotection. Published in Growth Hormone & IGF Research.

Derek (More Plates More Dates) has discussed GHRP-6 as the “old school” GH peptide choice, noting that while it produces solid GH release, the appetite spike makes it unsuitable for anyone in a caloric deficit. He generally recommends Ipamorelin + CJC-1295 as the modern standard due to the cleaner side effect profile.

Safety

Common Side Effects

Side Effect	Frequency	Notes
Intense hunger	~80%	Onset 20–30 min post-injection, lasts 30–60 min. Dose-dependent
Water retention	~30%	Mild, especially first 2–3 weeks. Indicates GH elevation
Numbness/tingling	~15%	Carpal tunnel-like. Dose-dependent. Reduce dose if persistent
Cortisol elevation	~20% (at >100 mcg)	Measurable at higher doses. Clinically significant only at aggressive dosing
Injection-site reaction	~10%	Minor redness, soreness. Rotate sites
Headache	~10%	Usually mild and transient
Prolactin elevation	~10% (at >100 mcg)	Mild. Monitor for galactorrhea at high doses
Dizziness/lightheadedness	~5%	Transient, may relate to blood sugar fluctuations in fasted state

Critical Warnings

Appetite management is the central challenge. The hunger spike is intense and can derail dietary discipline. If your goal is fat loss or caloric restriction, GHRP-6 is actively working against you. Use Ipamorelin instead.

Cortisol elevation at high doses. Chronic cortisol elevation impairs recovery, promotes visceral fat storage, and disrupts sleep — the opposite of what you want from a GH peptide. Keep doses at 100 mcg and avoid 3x daily dosing at 200+ mcg.

Fasting is mandatory. Injecting GHRP-6 in a fed state wastes the peptide. Insulin suppresses GH release at the pituitary level.

Not FDA-approved. GHRP-6 is not approved for human therapeutic use in any jurisdiction. All use is experimental.

Banned by WADA. Tested athletes cannot use GHRP-6.

Cancer precaution. Growth hormone promotes cell growth. Do not use with active malignancies, recent cancer history, or significant cancer risk factors.

Blood sugar monitoring. The combination of GH elevation (which reduces insulin sensitivity) and intense appetite (which drives carbohydrate cravings) can impact blood sugar management. Users with diabetes or pre-diabetes should monitor glucose closely.

Do Not Use If

• Active cancer or tumor history
• Active acromegaly or pituitary tumors
• Uncontrolled diabetes (GH reduces insulin sensitivity)
• Eating disorders (the appetite stimulation can be triggering)
• Pregnant or breastfeeding
• Under 18 (growth plates still active)
• Subject to WADA/USADA testing

What Comes Next

• Pair with CJC-1295 in the Growth Hormone Stack — the standard GH peptide combination
• Want cleaner GH release? — Ipamorelin Protocol delivers similar GH without the appetite spike
• Compare all GH options — Growth Hormone Peptides Compared
• Consider MK-677 for oral GH boosting with similar appetite effects — MK-677 Protocol
• Use the Reconstitution Calculator for exact unit counts